Menu
Back to Journals » Drug Design, Development and Therapy » Volume 13
A novel non-invasive monitoring assay of 5-azacitidine efficacy using global DNA methylation of peripheral blood in myelodysplastic syndrome
Authors Asano M, Ohyashiki JH, Kobayashi-Kawana C, Umezu T, Imanishi S, Azuma K, Akahane D, Fujimoto H, Ito Y, Ohyashiki K
Received 18 November 2018
Accepted for publication 4 April 2019
Published 30 May 2019 Volume 2019:13 Pages 1821—1833
DOI https://doi.org/10.2147/DDDT.S195071
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Tuo Deng
Michiyo Asano,1 Junko H Ohyashiki,2 Chiaki Kobayashi-Kawana,1 Tomohiro Umezu,1,3 Satoshi Imanishi,3 Kenko Azuma,3 Daigo Akahane,1 Hiroaki Fujimoto,1 Yoshikazu Ito,1 Kazuma Ohyashiki1
1Department of Hematology, Tokyo Medical University, Tokyo, Japan; 2Department of Advanced Cellular Therapy, Tokyo Medical University, Tokyo, Japan; 3Department of Molecular Oncology, Institute of Medical Science, Tokyo Medical University, Tokyo, Japan
Purpose: Monitoring response and resistance to 5-azacitidine (AZA) is essential when treating patients with myelodysplastic syndrome (MDS). To quantify methylated DNA not only in the promoter region but also in the gene body, we established a single-molecule methylation assay (SMMA).
Patients and methods: We first investigated the methylation extent (expressed as methylation index [MI]) by SMMA among 28 MDS and 6 post-MDS acute myeloid leukemia patients. We then analyzed the MI in 13 AZA-treated patients.
Results: Whole-blood DNA from all 34 patients had low MI values compared with healthy volunteers (P<0.0001). DNA hypomethylation in MDS patients was more evident in neutrophils (P=0.0008) than in peripheral mononuclear cells (P=0.0713). No consistent pattern of genome-wide DNA hypomethylation was found among MDS subtypes or revised International Prognostic Scoring System (IPSS-R) categories; however, we found that the MI was significantly increased for patients at very high risk who were separated by the new cytogenetic scoring system for IPSS-R (P=0.0398). There was no significant difference in MI before AZA, regardless of the response to AZA (P=0.8689); however, sequential measurement of MI in peripheral blood demonstrated that AZA non-responders did not have normalized MI at the time of next course of AZA (P=0.0352).
Conclusion: Our results suggest that sequential SMMA of peripheral blood after AZA may represent a non-invasive monitoring marker for AZA efficacy in MDS patients.
Keywords: myelodysplastic syndrome, azacytidine, peripheral blood, methylation index
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.